Pancreatic Cancer Research

ResearcherCross Cancer InstituteActive in the last 2 years

Christina Kim

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3847-2583; OpenAlex author ID A5021190839, A5075972279. Sources: OpenAlex.

Their work

Papers
11 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
35
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: none · 2015: none · 2016: none · 2017: none · 2018: 1 paper · 2019: 1 paper · 2020: none · 2021: 1 paper · 2022: 2 papers · 2023: 1 paper · 2024: 1 paper · 2025: none · 2026: 3 papers

Papers 11

  1. Addressing the distressing: Pancreatic enzyme replacement therapy mitigates abdominal symptoms and weight loss during chemotherapy for advanced pancreatic canc… First author DOI 10.1002/ncp.70096↗
  2. DNA Repair gene alterations and efficacy from gemcitabine and nab-paclitaxel with/without durvalumab and tremelimumab in metastatic pancreatic ductal adenocarc… Co-author DOI 10.1038/s41467-026-70120-z↗
  3. Clinical and Molecular Correlates of Circulating Tumor Fraction in Patients with Metastatic Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-26-0793↗
  4. Canadian National Pancreas Conference 2023: A Review of Multidisciplinary Engagement in Pancreatic Cancer Care. Co-author DOI 10.3390/curroncol31100461↗
  5. The impact of early palliative care on the quality of life of patients with advanced pancreatic cancer: The IMPERATIVE case-crossover study. Co-author DOI 10.1007/s00520-023-07709-3↗
  6. The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal a… Co-author DOI 10.1038/s41467-022-32591-8↗
  7. Treatment Patterns, Toxicity, and Outcomes of Older Adults With Advanced Pancreatic Cancer Receiving First-line Palliative Chemotherapy. Last author DOI 10.1097/coc.0000000000000882↗
  8. Utility of the modified frailty index in predicting toxicity and cancer outcomes for older adults with advanced pancreatic cancer receiving first-line palliati… Co-author DOI 10.1016/j.jgo.2020.07.004↗
  9. Real-world Outcomes Among Patients Treated With Gemcitabine-based Therapy Post-FOLFIRINOX Failure in Advanced Pancreatic Cancer. Co-author DOI 10.1097/coc.0000000000000625↗
  10. Predictive Impact of Clinical Benefit in Chemotherapy-treated Advanced Pancreatic Cancer Patients in Northern Alberta. Co-author DOI 10.1097/coc.0000000000000385↗
  11. Real-world impact of availability of adjuvant therapy on outcomes in patients with resected pancreatic adenocarcinoma: a Canadian Cancer Agency experience. Co-author DOI 10.1097/coc.0b013e318209d36c↗

Closest collaborators

The 25 strongest of 35 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Sharlene Gill · 6 shared papers, 2012–2026 · strength 0.86
  2. Ravi Ramjeesingh · 4 shared papers, 2022–2026 · strength 0.70
  3. Mustapha Ali Tehfe · 3 shared papers, 2022–2026 · strength 0.54
  4. Petr Kavan · 3 shared papers, 2022–2026 · strength 0.54
  5. James Thomas Topham · 3 shared papers, 2022–2026 · strength 0.54
  6. Félix Couture · 3 shared papers, 2022–2026 · strength 0.54
  7. Derek J. Jonker · 3 shared papers, 2022–2026 · strength 0.54
  8. Jennifer Jane Knox · 3 shared papers, 2022–2026 · strength 0.54
  9. David F. Schaeffer · 3 shared papers, 2022–2026 · strength 0.54
  10. Daniel John Renouf · 3 shared papers, 2022–2026 · strength 0.54
  11. Chris J. O’Callaghan · 3 shared papers, 2022–2026 · strength 0.54
  12. Joanna M. Karasinska · 2 shared papers, 2026 · strength 0.42
  13. George Zogopoulos · 2 shared papers, 2024–2026 · strength 0.37
  14. David E. Dawe · 2 shared papers, 2021–2022 · strength 0.34
  15. Rebekah Rittberg · 2 shared papers, 2021–2022 · strength 0.34
  16. Vera Christine Mazurak · 1 shared paper, 2026 · strength 0.33
  17. Vickie Elaine Baracos · 1 shared paper, 2026 · strength 0.33
  18. Pamela N. Klassen · 1 shared paper, 2026 · strength 0.33
  19. Michael B. Sawyer · 1 shared paper, 2026 · strength 0.33
  20. Yoo‐Joung Ko · 2 shared papers, 2022–2026 · strength 0.33
  21. Erica S. Tsang · 2 shared papers, 2019–2024 · strength 0.27
  22. Jennifer L. Spratlin · 2 shared papers, 2018–2019 · strength 0.21
  23. Steve Gallinger · 1 shared paper, 2026 · strength 0.21
  24. Faiyaz Notta · 1 shared paper, 2026 · strength 0.21
  25. Benjamin Adam Goldenberg · 1 shared paper, 2023 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.